Circulating tumor cells, disease progression, and survival in metastatic breast cancer
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
复制标题
DOI：
10.1056/nejmoa040766
复制
发表时间：
2004-08-19
影响因子：
158.5
通讯作者：
Hayes, DF
中科院分区：
文献类型：
--
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
背景：我们检验了循环肿瘤细胞水平可预测转移性乳腺癌患者生存期这一假设。
方法：在一项前瞻性、多中心研究中，我们对177例有可测量转移性乳腺癌的患者在开始新的治疗方案前以及首次随访时的循环肿瘤细胞水平进行了检测。疾病进展情况或对治疗的反应是通过参与研究的各中心的标准影像学检查来确定的。
结果：根据患者开始针对转移性疾病的新治疗前（基线水平）的循环肿瘤细胞水平对结果进行评估。在一个训练集中，与每7.5毫升全血中循环肿瘤细胞少于5个的组相比，每7.5毫升全血中循环肿瘤细胞水平等于或高于5个的患者中位无进展生存期更短（2.7个月对7.0个月，P<0.001），总生存期也更短（10.1个月对>18个月，P<0.001）。
BACKGROUND:We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer.METHODS:In a prospective, multicenter study, we tested 177 patients with measurable metastatic breast cancer for levels of circulating tumor cells both before the patients were to start a new line of treatment and at the first follow-up visit. The progression of the disease or the response to treatment was determined with the use of standard imaging studies at the participating centers.RESULTS:Outcomes were assessed according to levels of circulating tumor cells at baseline, before the patients started a new treatment for metastatic disease. Patients in a training set with levels of circulating tumor cells equal to or higher than 5 per 7.5 ml of whole blood, as compared with the group with fewer than 5 circulating tumor cells per 7.5 ml, had a shorter median progression-free survival (2.7 months vs. 7.0 months, P18 months, P